Hoong Kai Chua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hoong Kai Chua has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Keisuke Ejima
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
4 shared publications Yuqian Wang
Lee Kong Chian School of Medicine Nanyang Technological University Singapore Singapore
4 shared publicationsDavid Chien Lye
Lee Kong Chian School of Medicine Nanyang Technological University Singapore Singapore
3 shared publicationsPo Ying Chia
Lee Kong Chian School of Medicine Nanyang Technological University Singapore Singapore
3 shared publicationsSean W. X. Ong
National Center for Infectious Diseases (NCID) Singapore Singapore
3 shared publicationsAnanya Singh
Lee Kong Chian School of Medicine Nanyang Technological University Singapore Singapore
2 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (2) , e70823
Comparing Cross‐Sectional and Longitudinal Study Designs for Accurate Viral Dynamics Estimation: Insights From the NBA Cohort Data
Viral load data provide critical insights into host‐pathogen interactions and guide clinical and public health decisions. Because frequent testing is often infeasible, viral dynamics models are used to reconstruct infection trajectories, but optimal sampling strategies remain unclear. We compared two approaches for collecting SARS‐CoV‐2 viral load data: cross‐sectional sampling (one measurement at symptom onset) and longitudinal sampling (every 3 days after onset) under constraints on the total number of tests and tests per individual. A viral dynamics model was first fitted to data from the National Basketball Association cohort, and the estimated parameters were treated as ground truth. Synthetic data were then generated under each sampling design, refitted, and evaluated for accuracy in estimating viral load over 30 days, peak viral load, peak time, and viral shedding duration. Longitudinal sampling consistently yielded lower root mean squared error and narrower one standard deviation interval than cross‐sectional sampling. Peak timing and viral shedding duration were unbiased under both designs, but cross‐sectional designs underestimated peak viral load and produced wider one standard deviation intervals. Coverage of viral load estimates was markedly higher for longitudinal designs (> 0.90) compared with cross‐sectional ones (~0.10). Accuracy and coverage exceeded 0.96 even with just two tests per individual, with little additional benefit from more tests. In conclusion, longitudinal sampling—despite limited data—substantially improves accuracy and precision of viral load estimation compared with cross‐sectional designs. These findings highlight efficient strategies for study design and resource allocation in infectious disease research.
- 1 February 2026
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (2) , e70823
Open AccessComparing Cross‐Sectional and Longitudinal Study Designs for Accurate Viral Dynamics Estimation: Insights From the NBA Cohort Data
Viral load data provide critical insights into host‐pathogen interactions and guide clinical and public health decisions. Because frequent testing is often infeasible, viral dynamics models are used to reconstruct infection trajectories, but optimal sampling strategies remain unclear. We compared two approaches for collecting SARS‐CoV‐2 viral load data: cross‐sectional sampling (one measurement at symptom onset) and longitudinal sampling (every 3 days after onset) under constraints on the total number of tests and tests per individual. A viral dynamics model was first fitted to data from the National Basketball Association cohort, and the estimated parameters were treated as ground truth. Synthetic data were then generated under each sampling design, refitted, and evaluated for accuracy in estimating viral load over 30 days, peak viral load, peak time, and viral shedding duration. Longitudinal sampling consistently yielded lower root mean squared error and narrower one standard deviation interval than cross‐sectional sampling. Peak timing and viral shedding duration were unbiased under both designs, but cross‐sectional designs underestimated peak viral load and produced wider one standard deviation intervals. Coverage of viral load estimates was markedly higher for longitudinal designs (> 0.90) compared with cross‐sectional ones (~0.10). Accuracy and coverage exceeded 0.96 even with just two tests per individual, with little additional benefit from more tests. In conclusion, longitudinal sampling—despite limited data—substantially improves accuracy and precision of viral load estimation compared with cross‐sectional designs. These findings highlight efficient strategies for study design and resource allocation in infectious disease research.
- Open Access
- 6 August 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70521
Modeling Antibody Kinetics Post‐mRNA Booster Vaccination and Protection Durations Against SARS‐CoV‐2 Infection
Understanding the dynamics of SARS‐CoV‐2 antibody levels post‐booster vaccination is important to inform their durations of protection. Longitudinal antibody data was collected on the day of booster vaccination, as well as 28, 180, and 360 days after. Using nonlinear mixed effects models, we mapped the kinetics of binding IgA and IgG against wild‐type (WT) and Omicron BA.1 spike proteins. Furthermore, we analyzed the association between antibody levels and risk of SARS‐CoV‐2 vaccine breakthrough infection through survival analyzes, and predicted durations of protection against infection. We found that the antibody response waned more rapidly following the Pfizer/BioNTech BNT162b2 booster compared to the Moderna mRNA‐1273 booster. However, individuals boosted with the Pfizer vaccine exhibited a steeper rebound in antibody levels after infection. Faster postinfection antibody growth rates were observed in the elderly, females, and those with late infections. High antibody levels for WT IgG and BA.1 IgA at day 28 post‐booster were associated with reduced infection risk; hazard ratios were 0.47 (95% CI [0.22, 0.98]) and 0.36 (95% CI [0.17, 0.78]), respectively, compared to low levels. Time‐varying antibody levels showed better survival model fits. At medium COVID‐19 case incidence (621 cases per million per day), a binding BA.1 IgA response of at least 20% is needed to sustain 80% protection against infection over 155 days post‐booster. Our estimates of protection durations against SARS‐CoV‐2 infection post‐booster vaccination may help inform the ideal frequency of boosters.
- 6 August 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70521
Open AccessModeling Antibody Kinetics Post‐mRNA Booster Vaccination and Protection Durations Against SARS‐CoV‐2 Infection
Understanding the dynamics of SARS‐CoV‐2 antibody levels post‐booster vaccination is important to inform their durations of protection. Longitudinal antibody data was collected on the day of booster vaccination, as well as 28, 180, and 360 days after. Using nonlinear mixed effects models, we mapped the kinetics of binding IgA and IgG against wild‐type (WT) and Omicron BA.1 spike proteins. Furthermore, we analyzed the association between antibody levels and risk of SARS‐CoV‐2 vaccine breakthrough infection through survival analyzes, and predicted durations of protection against infection. We found that the antibody response waned more rapidly following the Pfizer/BioNTech BNT162b2 booster compared to the Moderna mRNA‐1273 booster. However, individuals boosted with the Pfizer vaccine exhibited a steeper rebound in antibody levels after infection. Faster postinfection antibody growth rates were observed in the elderly, females, and those with late infections. High antibody levels for WT IgG and BA.1 IgA at day 28 post‐booster were associated with reduced infection risk; hazard ratios were 0.47 (95% CI [0.22, 0.98]) and 0.36 (95% CI [0.17, 0.78]), respectively, compared to low levels. Time‐varying antibody levels showed better survival model fits. At medium COVID‐19 case incidence (621 cases per million per day), a binding BA.1 IgA response of at least 20% is needed to sustain 80% protection against infection over 155 days post‐booster. Our estimates of protection durations against SARS‐CoV‐2 infection post‐booster vaccination may help inform the ideal frequency of boosters.
- Open Access
- 13 March 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-9
Age- and vaccination status-dependent isolation guidelines based on simulation of SARS-CoV-2 Delta cases in Singapore
Background In the absence of effective pharmaceutical interventions early in an infectious disease outbreak, non-pharmaceutical measures, especially isolating infected individuals, critically limit its impact. The ongoing COVID-19 pandemic has sparked debates on optimal isolation guidelines. This study proposes a variable isolation period approach (variable-period approach), tailoring isolation durations for distinct population groups with varied viral load dynamics. Methods To compare our variable-period approach with a fixed-period strategy, we developed a simulation model generating synthetic longitudinal SARS-CoV-2 viral load data. The data was generated from the viral dynamics model parameterized using SARS-CoV-2 Delta patient data in Singapore, accounting for age and vaccination status. Results Findings show that age and vaccination status significantly influence viral dynamics, with younger age and vaccination linked to shorter viral shedding durations. The variable-period framework suggests longer isolation lengths for older and unvaccinated individuals. By setting the leaking risk (risk of remaining infectious at the end of isolation) below 10%, the optimal fixed-period isolation is 14 days, with an average excess isolation burden of 7.4 unnecessary days. In contrast, the variable-period guideline reduces the excess isolation burden to 6.0 days, with the optimal isolation periods ranging from 9 to 16 days, depending on the population group. We confirmed similar results when we used the effective reproduction number as an alternative to the leaking risk. Conclusions In this case, study using the SARS-CoV-2 Delta variant, our analysis demonstrates that unnecessary time spent in isolation can be reduced by adopting variable-period guidelines based on patient characteristics.
- 13 March 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-9
Open AccessAge- and vaccination status-dependent isolation guidelines based on simulation of SARS-CoV-2 Delta cases in Singapore
Background In the absence of effective pharmaceutical interventions early in an infectious disease outbreak, non-pharmaceutical measures, especially isolating infected individuals, critically limit its impact. The ongoing COVID-19 pandemic has sparked debates on optimal isolation guidelines. This study proposes a variable isolation period approach (variable-period approach), tailoring isolation durations for distinct population groups with varied viral load dynamics. Methods To compare our variable-period approach with a fixed-period strategy, we developed a simulation model generating synthetic longitudinal SARS-CoV-2 viral load data. The data was generated from the viral dynamics model parameterized using SARS-CoV-2 Delta patient data in Singapore, accounting for age and vaccination status. Results Findings show that age and vaccination status significantly influence viral dynamics, with younger age and vaccination linked to shorter viral shedding durations. The variable-period framework suggests longer isolation lengths for older and unvaccinated individuals. By setting the leaking risk (risk of remaining infectious at the end of isolation) below 10%, the optimal fixed-period isolation is 14 days, with an average excess isolation burden of 7.4 unnecessary days. In contrast, the variable-period guideline reduces the excess isolation burden to 6.0 days, with the optimal isolation periods ranging from 9 to 16 days, depending on the population group. We confirmed similar results when we used the effective reproduction number as an alternative to the leaking risk. Conclusions In this case, study using the SARS-CoV-2 Delta variant, our analysis demonstrates that unnecessary time spent in isolation can be reduced by adopting variable-period guidelines based on patient characteristics.
- Open Access
- 16 January 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (1) , e70174
Defining the Critical Requisites for Accurate Simulation of SARS‐CoV‐2 Viral Dynamics: Patient Characteristics and Data Collection Protocol
Mathematical models of viral dynamics are crucial in understanding infection trajectories. However, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) viral load data often includes limited sparse observations with significant heterogeneity. This study aims to: (1) understand the impact of patient characteristics in shaping the temporal viral load trajectory and (2) establish a data collection protocol (DCP) to reliably reconstruct individual viral load trajectories. We collected longitudinal viral load data for SARS‐CoV‐2 Delta and Omicron variants from 243 patients in Singapore (2021–2022). A viral dynamics model was calibrated using patients' age, symptom presence, and vaccination status. We accessed associations between these patient characteristics and aspects of viral dynamics using linear regression models. We evaluated the accuracy of viral load trajectory estimation under different simulated DCPs by varying patient numbers, test frequencies, and test intervals. Older unvaccinated individuals had a longer viral shedding duration due to lower infection and cell death rates. Higher peak viral loads were found in older, symptomatic, and vaccinated individuals, with earlier peaks in younger vaccinated individuals. Symptom presence and vaccination resulted in a shorter time from infection to diagnosis. To accurately estimate viral dynamics, more frequent tests, longer test intervals, and larger patient samples are required. For 500 patients, a 21‐day follow‐up with measurements every 3 days and an 8‐day follow‐up with daily measurements was optimal for the Delta and Omicron variants, respectively. Patient characteristics significantly impacted viral dynamics. Our analytic approach and recommended DCPs can enhance preparedness and response to emerging pathogens beyond SARS‐CoV‐2.
- 16 January 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (1) , e70174
Open AccessDefining the Critical Requisites for Accurate Simulation of SARS‐CoV‐2 Viral Dynamics: Patient Characteristics and Data Collection Protocol
Mathematical models of viral dynamics are crucial in understanding infection trajectories. However, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) viral load data often includes limited sparse observations with significant heterogeneity. This study aims to: (1) understand the impact of patient characteristics in shaping the temporal viral load trajectory and (2) establish a data collection protocol (DCP) to reliably reconstruct individual viral load trajectories. We collected longitudinal viral load data for SARS‐CoV‐2 Delta and Omicron variants from 243 patients in Singapore (2021–2022). A viral dynamics model was calibrated using patients' age, symptom presence, and vaccination status. We accessed associations between these patient characteristics and aspects of viral dynamics using linear regression models. We evaluated the accuracy of viral load trajectory estimation under different simulated DCPs by varying patient numbers, test frequencies, and test intervals. Older unvaccinated individuals had a longer viral shedding duration due to lower infection and cell death rates. Higher peak viral loads were found in older, symptomatic, and vaccinated individuals, with earlier peaks in younger vaccinated individuals. Symptom presence and vaccination resulted in a shorter time from infection to diagnosis. To accurately estimate viral dynamics, more frequent tests, longer test intervals, and larger patient samples are required. For 500 patients, a 21‐day follow‐up with measurements every 3 days and an 8‐day follow‐up with daily measurements was optimal for the Delta and Omicron variants, respectively. Patient characteristics significantly impacted viral dynamics. Our analytic approach and recommended DCPs can enhance preparedness and response to emerging pathogens beyond SARS‐CoV‐2.